Search - tctmd.com

Displaying 301 - 320 of 345

Sort: Relevancy | Date

News Conference News

EES Compared Favorably with SES In Two Pivotal Trials

November 08, 2011

News Conference News

Bioabsorbable Polymers, Scaffolds Offer Permanent Advantages

November 08, 2011

News Conference News

APICE-OCT: EES, ZES Yield Low Rates of Uncovered Struts in ACS

November 08, 2011

News Conference News

ZES, EES Noninferior to PES

November 07, 2011

News Conference News

Early Discontinuation of DAPT May Increase Risk of Stent Thrombosis

November 06, 2011

News Conference News

DES Noninferior for Survival Compared with BMS in STEMI

November 06, 2011

News Industry News

Abbott to Present New Data for Key Vascular Products at TCT 2011

November 03, 2011

News Industry News

Boston Scientific Announces Schedule of Events at TCT Scientific Symposium

November 01, 2011

News Industry News

Abbott Receives U.S. FDA Approval for Next-Generation XIENCE PRIME™ Drug Eluting Stent

November 01, 2011

News Daily News

Xience Shows Noninferior Late Loss to Cypher, Similar Hard Outcomes

October 17, 2011

News Industry News

Boston Scientific Launches Promus Element™ Stent System In China

October 17, 2011

News Industry News

Boston Scientific Begins Clinical Trial Enrollment for OMEGA™ Platinum Chromium Stent System

October 05, 2011

News Daily News

Meta-analysis: Everolimus-Eluting Stents Reduce Thrombosis vs. Other DES

September 14, 2011

News Daily News

Long-term Outcomes Similar for Biodegradable-Polymer, Permanent-Polymer DES

September 12, 2011

News Conference News

Two Trials Show Favorable Results with XIENCE V vs. Earlier DES, BMS

September 02, 2011

News Conference News

RESET: Largest Study to Date of Xience, Cypher Shows Noninferiority

August 31, 2011

News Conference News

Long-term Antiplatelet Therapy: All Risk, No Benefit

August 30, 2011

News Daily News

TRIAS HR Published: Genous Stent Doubles Target Lesion Failure

Leah Lawrence

August 23, 2011

News Daily News

No Apparent Advantage for Everolimus vs. Paclitaxel Stents in Diabetic Patients

L.A. McKeown

August 19, 2011

News Daily News

ESSENCE-DIABETES Published: Xience, Cypher Equally Equipped to Treat Diabetics

Caitlin E. Cox

August 03, 2011

Advertisement

EES Compared Favorably with SES In Two Pivotal Trials

Bioabsorbable Polymers, Scaffolds Offer Permanent Advantages

APICE-OCT: EES, ZES Yield Low Rates of Uncovered Struts in ACS

ZES, EES Noninferior to PES

Early Discontinuation of DAPT May Increase Risk of Stent Thrombosis

DES Noninferior for Survival Compared with BMS in STEMI

Abbott to Present New Data for Key Vascular Products at TCT 2011

Boston Scientific Announces Schedule of Events at TCT Scientific Symposium

Abbott Receives U.S. FDA Approval for Next-Generation XIENCE PRIME™ Drug Eluting Stent

Xience Shows Noninferior Late Loss to Cypher, Similar Hard Outcomes

Boston Scientific Launches Promus Element™ Stent System In China

Boston Scientific Begins Clinical Trial Enrollment for OMEGA™ Platinum Chromium Stent System

Meta-analysis: Everolimus-Eluting Stents Reduce Thrombosis vs. Other DES

Long-term Outcomes Similar for Biodegradable-Polymer, Permanent-Polymer DES

Two Trials Show Favorable Results with XIENCE V vs. Earlier DES, BMS

RESET: Largest Study to Date of Xience, Cypher Shows Noninferiority

Long-term Antiplatelet Therapy: All Risk, No Benefit

TRIAS HR Published: Genous Stent Doubles Target Lesion Failure

No Apparent Advantage for Everolimus vs. Paclitaxel Stents in Diabetic Patients

ESSENCE-DIABETES Published: Xience, Cypher Equally Equipped to Treat Diabetics

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content